Table 3 Clinicopathological characteristics of the patients in the Z0011 SLNB-alone arm and those in the current study
From: Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study
Characteristics | Eligible patients (n=142) | Z0011 SLNB alone (n = 436) | P value |
|---|---|---|---|
Age, median (range), years | 52 (26–82) | 54 (25–90) | - |
Age group, no. (%) | |||
 ≤ 50 | 68 (47.89) | 160 (37.6) | 0.03 |
 > 50 | 74 (52.11) | 266 (62.4) |  |
 Missing | 0 | 10 |  |
Clinical T stage, no. (%) | |||
 cT1 | 112 (78.87) | 303 (70.6) | 0.056 |
 cT2 | 30 (21.13) | 126 (29.4) |  |
 Missing | 0 | 7 |  |
Tumor histology, no. (%) | |||
 Ductal | 119 (83.80) | 356 (84.0) | 0.589 |
 Lobular | 15 (10.56) | 36 (8.5) |  |
 Other | 8 (5.63) | 32 (7.5) |  |
 Missing | 0 | 12 |  |
Hormone status, no. (%) | |||
 Positive | 117 (82.39) | 328 (83.7) | 0.726 |
 Negative | 25 (17.61) | 64 (16.3) |  |
 Missing | 0 | 44 |  |
Lymphovascular invasion, no. (%) | |||
 Present | 33 (32.67) | 113 (35.2) | 0.641 |
 Absent | 68 (67.33) | 208 (64.8) |  |
 Missing | 41 | 115 |  |
Number of positive SLNs, no. (%) | |||
 0–1 | 109 (76.76) | 324 (78.1) | 0.746 |
 ≥ 2 | 33 (23.24) | 91 (21.9) |  |
 Missing | 0 | 21 |  |
Adjuvant chemotherapy, no. (%) | |||
 Yes | 129 (90.85) | 253 (58.0) | < 0.001 |
 No/missing | 13 (9.15) | 183 (42.0) |  |
Adjuvant endocrine therapy, no. (%) | |||
 Yes | 115 (80.99) | 203 (46.6) | < 0.001 |
 No/missing | 27 (19.01) | 233 (53.4) |  |
Radiotherapy, no. (%) | |||
 Yes | 127 (89.44) | 277* (89.64) | 0.947 |
 No | 15 (10.56) | 32* (10.36) |  |